Phase 1 N=36 Study of DCR-AUD in Healthy Volunteers
Alcohol Use Disorder (AUD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 5; 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 5; 4; 0 Participants
Phase 1 N=20 Ketone Pharmacokinetic Study in HFrEF
Heart Failure With Reduced Ejection Fraction
Primary: Venous pH Measured Via Peripheral Blood — 7.30; 7.28 unitless
Phase 1 N=30 Neural Correlates of Lidocaine Analgesia
Anesthesia · Pain
Primary: Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition — 3.6 Z-score — p=0.004
Phase 1 N=5 Dendritic Cell Vaccination in Patients With Advanced Melanoma
Melanoma
Primary: Immune Response Measuring Increased Numbers of Peptide Specific T Cells as Calculated by the Tetramer Assay. — 0; 0; 0; 0 percent of CD8+ T cells
Phase 1 N=66 SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
Eosinophilic Esophagitis (EoE)
Primary: Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant — 1; 0; 1; 2 Participants
Phase 1 N=40 GLS-5700 in Dengue Virus-Naïve Adults
Healthy
Primary: Number of Participants With Serious Adverse Events From Day 0 Through Week 60 — 0; 0 participants
Phase 1 N=100 Regadenoson R-T Perfusion Imaging Trial
Coronary Artery Disease · Myocardial Perfusion Abnormalities
Primary: Detection of Coronary Artery Disease With Real-time Perfusion Echocardiography During Regadenoson Stress — 98; 98 Participants — p=<0.001
Phase 1 N=139 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Primary: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 Participants
Phase 1 N=243 Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices
Dementia
Primary: Provider Recruitment Feasibility — 1.44 Providers trained per month
Phase 1 N=53 A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
Rabies
Primary: Number of Participants Who Experienced a Local Solicited Adverse Event (AE) Post Dose 1 (Day 1) — 13; 15; 10; 5 Participants
Phase 1 N=41 Anthrax AV7909 Liquid vs Lyophilized
Anthrax · Anthrax Immunisation
Primary: Number of Participants With Serious Adverse Events (SAEs). — 0; 0 Participants
Phase 1 N=22 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease
Primary: Maximum Drug Concentration at Steady-state (Cmax,ss) of Vonoprazan — 16.2; 42.1 ng/mL
Phase 1 N=43 Boost Study 31380 (mHealth)
Addiction
Primary: Interaction Engagement, as Assessed by Interactions Completed — 7.3 interactions
Phase 1 N=38 Concentration-QT Study of Paroxetine in Healthy Adults
Anxiety Disorders
Primary: Change From Baseline in Corrected QT Interval by Fridericia (QTcF Interval) — 1.9; 1.0; 0.9; 2.2 Milliseconds